Phase 2 × Terminated × Triple Negative Breast Neoplasms × Clear all AMTEC IIT: Phase 2 Multiarm Study in TNBC
Phase 2 Terminated
24 enrolled 16 charts
INTEGRAL
Phase 2 Terminated
8 enrolled 10 charts
neoMono
Phase 2 Terminated
442 enrolled 42 charts
Olinvacimab With Pembrolizumab in Patients With mTNBC
Phase 2 Terminated
19 enrolled
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Phase 2 Terminated
24 enrolled
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Phase 2 Terminated
77 enrolled 18 charts
BIS-Program
Phase 2 Terminated
33 enrolled
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Phase 2 Terminated
26 enrolled
MK-2140-002
Phase 2 Terminated
102 enrolled 36 charts
ELEVATE TNBC
Phase 2 Terminated
92 enrolled 27 charts
TNBC
Phase 2 Terminated
115 enrolled 31 charts
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Phase 2 Terminated
6 enrolled
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
25 enrolled
PERSEVERE
Phase 2 Terminated
52 enrolled 16 charts
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Phase 2 Terminated
9 enrolled
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Phase 2 Terminated
30 enrolled 16 charts
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Phase 2 Terminated
315 enrolled 73 charts
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Phase 2 Terminated
6 enrolled 8 charts
Sitravatinib in Metastatic Breast Cancer
Phase 2 Terminated
3 enrolled 13 charts
TENACITY
Phase 2 Terminated
18 enrolled 10 charts
TARA
Phase 2 Terminated
1 enrolled 11 charts
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Phase 2 Terminated
8 enrolled 7 charts
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Phase 2 Terminated
11 enrolled 9 charts
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase 2 Terminated
148 enrolled 9 charts
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Phase 2 Terminated
5 enrolled 12 charts
0927GCC
Phase 2 Terminated
5 enrolled 7 charts
DETECT
Phase 2 Terminated
12 enrolled
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Terminated
102 enrolled 51 charts
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
4 enrolled 10 charts
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Phase 2 Terminated
29 enrolled 10 charts
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Phase 2 Terminated
48 enrolled
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
23 enrolled 11 charts
A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
Phase 2 Terminated
6 enrolled
CONTESSA TRIO
Phase 2 Terminated
294 enrolled
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Phase 2 Terminated
6 enrolled
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
Phase 2 Terminated
12 enrolled
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Phase 2 Terminated
32 enrolled 12 charts
BATON-BC
Phase 2 Terminated
30 enrolled 10 charts
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Phase 2 Terminated
13 enrolled 13 charts
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Phase 2 Terminated
3 enrolled
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Phase 2 Terminated
19 enrolled 9 charts
VICTOR3
Phase 2 Terminated
4 enrolled
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Terminated
14 enrolled 11 charts
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Phase 2 Terminated
1 enrolled
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Phase 2 Terminated
12 enrolled 9 charts
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
Phase 2 Terminated
6 enrolled 8 charts
META2
Phase 2 Terminated
3 enrolled
Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer
Phase 2 Terminated
3 enrolled
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase 2 Terminated
5 enrolled 3 charts